Literature DB >> 30673828

A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients.

Ryungsa Kim1, Ami Kawai2, Megumi Wakisaka2, Yuri Funaoka2, Naomi Yasuda2, Masayuki Hidaka3, Yukitaka Morita3, Shoichro Ohtani4, Mitsuya Ito4, Koji Arihiro5.   

Abstract

Tumor-infiltrating lymphocytes are an important prognostic factor after neoadjuvant chemotherapy (NAC) in patients with breast cancer. Natural killer (NK) cells play critical roles in antitumor immune surveillance. Here, we assessed the relationship between peripheral natural killer (pNK) cell activity, tumor microenvironmental factors (TMEFs), and the therapeutic efficacy of preoperative chemotherapy in patients with breast cancer. In a cohort of 39 patients diagnosed with stage II-IV breast cancer who received NAC, we measured pNK cell activity by chromium release assay and assessed TMEF levels by next-generation sequencing. Following NAC, pNK cell activity was increased in 24/39 patients but decreased in 15/39 patients. Increased pNK cell activity following preoperative chemotherapy was associated significantly with the disappearance of axillary lymph node metastasis (Ax+; p = 0.0235). Increased pNK cell activity remained significantly associated with the disappearance of Ax+ in multivariate logistic regression analysis (OR 5.41, 95% CI 1.19-24.52, p = 0.0283). A Grade 2 or higher effect of NAC was associated with high pre-NAC cytotoxic T lymphocyte-associated protein 4 (CTLA-4) levels (p = 0.0281) and elevated post-NAC NK (p = 0.0005) cells and transforming growth factor-beta (TGF-β; p = 0.0350) levels. The disappearance of Ax+ was associated with high pre-NAC CTLA-4 levels (p = 0.0278) and elevated CD4 levels after NAC (p = 0.0250). The systemic activation of pNK cells after NAC may improve metastatic tumor elimination in patients with breast cancer owing to a release from local immunosuppression, and immune activation in the tumor microenvironment.

Entities:  

Keywords:  Breast cancer; Immune response; Peripheral natural killer cell (pNK) activity; Preoperative chemotherapy; Transforming growth factor β; Tumor microenvironment

Mesh:

Substances:

Year:  2019        PMID: 30673828     DOI: 10.1007/s00262-019-02305-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

Review 1.  Modeling chemical effects on breast cancer: the importance of the microenvironment in vitro.

Authors:  Molly M Morgan; Linda A Schuler; Jordan C Ciciliano; Brian P Johnson; Elaine T Alarid; David J Beebe
Journal:  Integr Biol (Camb)       Date:  2020-03-06       Impact factor: 2.192

Review 2.  The role of the natural killer (NK) cell modulation in breast cancer incidence and progress.

Authors:  Ehsan Razeghian; Mahdis Chahar Kameh; Sepehr Shafiee; Farima Khalafi; Fehimeh Jafari; Mohammadali Asghari; Kiarash Kazemi; Saba Ilkhani; Siavash Shariatzadeh; Arvin Haj-Mirzaian
Journal:  Mol Biol Rep       Date:  2022-08-25       Impact factor: 2.742

Review 3.  Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.

Authors:  Paola Ferrari; Cristian Scatena; Matteo Ghilli; Irene Bargagna; Giulia Lorenzini; Andrea Nicolini
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

4.  Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study.

Authors:  Elisa C Toffoli; Maike G Sweegers; Hetty J Bontkes; Teatske M Altenburg; Henk M W Verheul; Hans J van der Vliet; Tanja D de Gruijl; Laurien M Buffart
Journal:  Physiol Rep       Date:  2021-06

Review 5.  The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery.

Authors:  Sofia Batalha; Sofia Ferreira; Catarina Brito
Journal:  Cancers (Basel)       Date:  2021-03-15       Impact factor: 6.639

Review 6.  Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice.

Authors:  Jinguo Zhang; Shuaikang Pan; Chen Jian; Li Hao; Jie Dong; Qingqing Sun; Hongwei Jin; Xinghua Han
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.